MIBI for kidney
Research type
Research Study
Full title
A feasibility study to investigate acceptability of 99m Tc SestaMIBI SPECT/CT for kidney mass characterisation.
IRAS ID
282927
Contact name
Maxine Tran
Contact email
ISRCTN Number
ISRCTN12572202
Duration of Study in the UK
2 years, 11 months, 30 days
Research summary
The diagnosis of kidney tumours is increasing, and results in an increasing amount of kidney surgery being performed. Not all kidney tumours are cancer, and up to 3 in 10 can be benign. Currently, the only way to tell whether a tumour is benign or cancer is to have a biopsy. However, this also has risks such as pain, bleeding and patients worry about potential 'spillage' of the tumour from the biopsy. Many hospitals do not offer renal tumour biopsy.
New studies from the USA and Sweden have shown that a type of nuclear medicine scan called 'Sestamibi' (MIBI) can distinguish renal cancer from benign tumours. MIBI scans are currently being used in the NHS for other diseases such as parathyroid and heart muscle imaging and are known to be very safe, painless and widely available.
This study will investigate if MIBI can be used for patients diagnosed with renal masses in the UK. Adult patients diagnosed with a renal mass larger than 2cm will be invited to participate by having a MIBI scan prior to their scheduled biopsy or surgery For this feasibility study, it is planned to recruit 30 patients. The second part of this study is to explore the acceptability of MIBI scans by interviewing and surveying perception amongst patients and clinicians (aim for 20 semi-structured interviews).REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
20/YH/0279
Date of REC Opinion
26 Nov 2020
REC opinion
Further Information Favourable Opinion